Literature DB >> 18303389

Recurrent Myocilin Asn480Lys glaucoma causative mutation arises de novo in a family of Andean descent.

Maria Luisa Guevara-Fujita1, Rodolfo A Perez-Grossmann, Alejandro Estrada-Cuzcano, Hemant Pawar, Enrique Vargas, Julia E Richards, Ricardo Fujita.   

Abstract

PURPOSE: To search for MYOC mutations in Peruvian primary open angle glaucoma (POAG) families. PATIENTS AND METHODS: Two patients from each of the 11 POAG Peruvian families were screened for sequence variants in MYOC coding exons by conformational sensitive gel electrophoresis and sequencing was performed on the samples indicating probable sequence changes.
RESULTS: We detected 2 families bearing distortions of conformational sensitive gel electrophoresis indicating mutations. Sequencing of these samples revealed coding sequence changes. A native Andean descent family presented with a MYOC mutation, Asn480Lys (C-->G at nucleotide 1440). This is different from the previously reported C-->A change at nucleotide 1440 that causes Asn480Lys in 2 unrelated French and Dutch families with glaucoma of variable expressivity, and indicates a third independent event. A second family of admixed origin showed the presence of the known Arg76Lys polymorphism.
CONCLUSIONS: In the study of MYOC variants in 11 POAG Peruvian families, we have found a family of ethnically admixed origin with polymorphism Arg76Lys and a family of Andean descent bearing a third event of the Asn480Lys, the MYOC mutation that has been reported in the highest number of POAG patients (>80 cases). Analysis of this family could contribute with information about disease manifestation, progression, and treatment response in the context of a distinct genetic background and also climatic, altitude, and socioeconomical conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303389     DOI: 10.1097/IJG.0b013e318133fc5b

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  Novel and known MYOC exon 3 mutations in an admixed Peruvian primary open-angle glaucoma population.

Authors:  Veronica Mendoza-Reinoso; Teja S Patil; Maria L Guevara-Fujita; Silvia Fernández; Enrique Vargas; Wilder Castillo-Herrera; Rodolfo Perez-Grossmann; Frank Lizaraso-Caparó; Julia E Richards; Ricardo Fujita
Journal:  Mol Vis       Date:  2012-08-08       Impact factor: 2.367

Review 2.  Common and rare myocilin variants: Predicting glaucoma pathogenicity based on genetics, clinical, and laboratory misfolding data.

Authors:  Hailee F Scelsi; Brett M Barlow; Emily G Saccuzzo; Raquel L Lieberman
Journal:  Hum Mutat       Date:  2021-06-24       Impact factor: 4.700

Review 3.  Genetics and genomics in Peru: Clinical and research perspective.

Authors:  Heinner Guio; Julio A Poterico; Kelly S Levano; Mario Cornejo-Olivas; Pilar Mazzetti; Gioconda Manassero-Morales; Manuel F Ugarte-Gil; Eduardo Acevedo-Vásquez; Milagros Dueñas-Roque; Alejandro Piscoya; Ricardo Fujita; Cesar Sanchez; Sandro Casavilca-Zambrano; Luis Jaramillo-Valverde; Yasser Sullcahuaman-Allende; Juan M Iglesias-Pedraz; Hugo Abarca-Barriga
Journal:  Mol Genet Genomic Med       Date:  2018-11       Impact factor: 2.183

Review 4.  Age at Glaucoma Diagnosis in Germline Myocilin Mutation Patients: Associations with Polymorphisms in Protein Stabilities.

Authors:  Tarin Tanji; Emily Cohen; Darrick Shen; Chi Zhang; Fei Yu; Anne L Coleman; Jie J Zheng
Journal:  Genes (Basel)       Date:  2021-11-16       Impact factor: 4.141

5.  Identification of MYOC gene mutation and polymorphism in a large Malay family with juvenile-onset open angle glaucoma.

Authors:  Z Mimivati; K Nurliza; M Marini; At Liza-Sharmini
Journal:  Mol Vis       Date:  2014-05-27       Impact factor: 2.367

Review 6.  Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations.

Authors:  Ryan Zukerman; Alon Harris; Alice Verticchio Vercellin; Brent Siesky; Louis R Pasquale; Thomas A Ciulla
Journal:  Genes (Basel)       Date:  2020-12-31       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.